Absci Corporation (ABSI)
NASDAQ (NGS) NASDAQ (NGS) Primary 
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study
Absci Corporation stock jumps after initiating dosing in its phase I/IIa ABS-201 study for androgenetic alopecia, seeking early safety and efficacy signals.
Absci Corporation (ABSI) Presents at Jefferies London Healthcare Conference 2025 Transcript
Absci Corporation ( ABSI ) Jefferies London Healthcare Conference 2025 November 18, 2025 4:30 AM EST Company Participants Sean McClain - Founder, CEO, President & Director Presentation Operator It's my pleasure to now introduce Sean McClain, CEO; and Zach Jonasson, CFO of Absci Corporation. Just a reminder, there will be a 20-minutes presentation following with 5 minutes Q&A.
Absci Corporation (ABSI) Q3 2025 Earnings Call Transcript
Absci Corporation ( ABSI ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Alexander Khan - VP of Finance & Head of Investor Relations Sean McClain - Founder, CEO, President & Director Zachariah Jonasson - Chief Business Officer & CFO Andreas Busch - Chief Innovation Officer & Member of Scientific Advisory Board Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division Brendan Smith - TD Cowen, Research Division Sean Laaman - Morgan Stanley, Research Division Gil Blum - Needham & Company, LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Srikripa Devarakonda - Truist Securities, Inc., Research Division Presentation Operator Thank you for standing by. My name is Rochelle, and I will be your operator today.
Absci Corporation (ABSI) Reports Q3 Loss, Lags Revenue Estimates
Absci Corporation (ABSI) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.24 per share a year ago.
Absci Corporation (ABSI) Q2 2025 Earnings Call Transcript
Absci Corporation (NASDAQ:ABSI ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Alexander Khan - VP of Finance & Head of Investor Relations Christian Stegmann - Senior Vice President of Drug Creation Sean McClain - Founder, CEO, President & Director Zachariah Jonasson - Chief Business Officer & CFO Conference Call Participants Alexander Xenakis - Unidentified Company Truist Securities - Unidentified Company Arseniy Shabashvili - Guggenheim Securities, LLC, Research Division Brendan Mychal Smith - TD Cowen, Research Division Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Gil Joseph Blum - Needham & Company, LLC, Research Division Morgan K. Gryga - Morgan Stanley, Research Division Steven Craig Dechert - KeyBanc Capital Markets Inc., Research Division Swayampakula Ramakanth - H.C.
Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates
Absci Corporation (ABSI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.22 per share a year ago.
Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy?
ABSCI CORP (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Absci Corporation (ABSI) Q1 2025 Earnings Call Transcript
Absci Corporation (NASDAQ:ABSI ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and Chief Executive Officer Zach Jonasson - Chief Financial Officer and Chief Business Officer Christian Stegmann - Senior Vice President of Drug Creation Conference Call Participants Arseniy Shabashvili - Guggenheim Securities Brendan Smith - TD Cowen Gil Blum - Needham & Company George Farmer - Scotiabank Debanjana Chatterjee - Jones Li Chen - H.C. Wainwright Operator Thank you for standing by, and welcome to Absci's First Quarter 2025 Business Update and Financial and Operating Results Conference Call.
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
Absci Corporation (ABSI) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.22 per share a year ago.
Absci Corporation: A Potential Turnaround Play In Biotech Amid A Tumultuous Market
Absci Corporation stock has dropped since January, driven by weak earnings and broader biotech sector pressures. Despite weak financials, Absci's internal pipeline, including ABS-101 and ABS-201, offers potential upside but increases burn rates and development risks. Strategic partnerships, like those with AMD and AstraZeneca, validate Absci's platform but have yet to generate significant revenue.
Which Healthcare Stock Is the Best Buy Right Now?
In the world of upstart pharmaceuticals and healthcare companies, timing is everything. These firms often struggle for an extended period of time before becoming profitable, but when they see success with a new product—or even clinical trial results suggesting a new product could be on the horizon—they can experience huge rallies in a very short period of time.
Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
